CVS returns Zepbound to drug plans
Digest more
Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past estimates, as demand for its blockbuster ...
The efficacy of Eli Lilly's new, still-in-development GLP-1 drug is gaining attention, but don't forget its older GLP-1 drugs ...
Morning Overview on MSN
Eli Lilly’s new obesity pill just stripped 85 pounds off patients in a late-stage trial — the steepest weight loss ever logged without a needle
Participants in Eli Lilly’s TRIUMPH-1 trial lost an average of roughly 85 pounds on the highest dose of retatrutide, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results